Your browser doesn't support javascript.
Early switch from cladribine to alemtuzumab in highly-active relapsing-remitting multiple sclerosis: A case report
Neuroimmunology Reports ; 2 (no pagination), 2022.
Article in English | EMBASE | ID: covidwho-2299562
ABSTRACT
Background Management of patients with multiple sclerosis (MS) and evidence of disease activity during treatment with cladribine tablets represents a challenging point. Objectives To report a patient with highly active multiple sclerosis (HAMS) who has been early switched from cladribine to alemtuzumab owing to tumultuous clinical and radiological activity Methods A single retrospective case report. Results. Treatment with alemtuzumab has led to a complete suppression of disease activity without any evidence of infections or acquired autoimmune diseases. Conclusion Our report suggests that an early switch from cladribine to alemtuzumab, may be safe and efficacious in selected HAMS cases.Copyright © 2022 The Authors
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Case report Language: English Journal: Neuroimmunology Reports Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Case report Language: English Journal: Neuroimmunology Reports Year: 2022 Document Type: Article